Immunron Chief Executive Officer Gary Jacob resigns amidst coronavirus cost-cutting
March 27, 2020Manufacturing and Production
The Chief Executive Officer of Immuron, Gary S. Jacob, has resigned as CEO and as a member of the Board …
FDA invokes emergency powers to authorise 30-minute, handheld COVID-19 test
March 27, 2020Medical Communications, Sales and Marketing COVID-19, FDA, Mesa Biotech, US, coronavirus
The FDA invoked Emergency Use Authorization powers to approve a rapid, handheld testing kit for COVID-19 coronavirus cases just days …
US now leads world in COVID-19 cases as report warns it could face 80,000 deaths in four months
March 27, 2020Medical Communications, Research and Development
The US now leads the world in total number of COVID-19 cases with more than 85,500 positives, ahead of China’s …
Top Ten most popular articles on Pharmafile.com this week
March 27, 2020Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing COVID-19, coronavirus
The COVID-19 global pandemic continues to dominate the news cycle. The first clinical trial using danoprevir (Ganovo) in treating COVID-19 …
British Prime Minister Boris Johnson tests positive for coronavirus
March 27, 2020Medical Communications COVID-19, Coroanvirus
British Prime Minister Boris Johnson has tested positive for coronavirus, developing mild symptoms over the last 24 hours which included …
Teva donates millions of hydroxychloroquine sulfate tablets, touted by Trump as coronavirus treatment
March 27, 2020Medical Communications Trump, coronavirus
Teva pharmaceuticals have said they will provide ten million doses of its anti-malaria drug hydroxychloroquine, which President Trump has been …
COVID-19 may significantly hurt the drug supply chains of the biggest pharmaceutical companies
March 27, 2020Medical Communications COVID-19, Coroanvirus, Wuhan Coronavirus, china coronavirus
The increasing spread of the COVID-19 coronavirus pandemic threatens the drug supply lines of the biggest pharmaceutical companies, including AstraZeneca, …
AbbVie won’t defend its patent for Kaletra so it can be made available for coronavirus treatment
March 26, 2020Business Services COVID-19, Ebola Drug, Wuhan Coronavirus, china coronavirus, coronavirus
AbbVie has announce it will not defend its patent to its HIV therapy Kaletra (lopinavir) so it can be made …
FDA approves BMS’ Zeposia in relapsing multiple sclerosis, but COVID-19 will delay its market entry
March 26, 2020Sales and Marketing Bristol-Myers Squibb, COVID-19, Zeposia, coronavirus, multiple sclerosis, pharma
Bristol-Myers Squibb has secured approval with the FDA for Zeposia (ozanimod) 0.92mg in relapsing forms of multiple sclerosis (RMS), but …
FDA will allow doctors to use convalescent plasma to treat critical COVID-19 patients
March 26, 2020Business Services COVID-19, China, Chinese Coronavirus, Wuhan Coronavirus, coronavirus
The FDA have announced they will allow doctors to use convalescent plasma, collected from people who recovered from COVID-19, to …
First for Japan with the approval of AstraZeneca’s Lokelma in hyperkalaemia
March 26, 2020Sales and Marketing AstraZeneca, Astra|Zeneca, Japan, Lokelma, hyperkalaemia, pharma
Japan’s Ministry of Health, Labour and Welfare has awarded approval to AstraZeneca’s Lokelma for the treatment of hyerkalaemia, marking the …
Gilead asks FDA to rescind its Orphan Drug status for potential coronavirus treatment following criticism
March 26, 2020Business Services China, Gilead, Wuhan Coronavirus, china coronavirus, coronavirus
Gilead Sciences has submitted a request for the FDA to rescind its offer of Orphan Drug designation for remdesivir in …
Novartis reveals hard-hitting five-year data for its gene therapy Zolgensma in spinal muscular atrophy
March 25, 2020Research and Development Novartis, Zolgensma, gene therapy, pharma, spinal muscular atrophy
Novartis has revealed five-year data on its gene therapy Zolgensma, boasting that the one-time infusion demonstrated “rapid, significant and clinically …
British government protecting high demand medicine for use in COVID-19 patients
March 25, 2020Research and Development COVID-19, china coronavirus, coronavirus
The British government has implemented new restrictions to protect high demand medicines for coronavirus patients. 80 medicines and being banned …
Results released from first clinical trial using Danoprevir to treat COVID-19
March 25, 2020Research and Development COVID, COVID-19, Wuhan, china coronavirus, coronavirus
The first clinical trial using danoprevir (Ganovo) in treating COVID-19 has released its results, showing that it is safe and …
FDA approves supplemental drug application for Pfizer’s EURCRISA in children with eczema
March 25, 2020Research and Development, Sales and Marketing eczema, eczema cream, eczema ointment
Pfizer announced that the FDA has approved its supplemental New Drug Application for EUCRISA ointment in treating 3 month year …
Eyeforpharma Barcelona 2020 is now a free virtual event
March 25, 2020Medical Communications, Research and Development COVID-19, Eyeforpharma Barcelona 2020, coronavirus, events, eyeforpharma, pharma
In light of the rapidly evolving impact of the COVID-19 virus, eyeforpharma has decided to turn eyeforpharma Barcelona 2020 into …
Demand for hydroxychloroquine soars after Trump says it can treat coronavirus
March 25, 2020Research and Development, Sales and Marketing COVID-19, Wuhan Coronavirus, china coronavirus, coronavirus, covid19
President Trump has continually touted the effectiveness of anti-malaria drug Hydroxychloroquine in treating coronavirus which has led to a jump …
AstraZeneca to leverage Silence Therapeutics’ siRNA expertise in $480mn deal
March 25, 2020Research and Development, Sales and Marketing AstraZeneca, Silence Therapeutics, collaboration, pharma
Silence Therapeutics has revealed it has struck a new collaboration with AstraZeneca which will trigger the “acceleration and re-prioritisation of …
Roche shows improved survival rates in new treatment for untreated acute myeloid leukaemia
March 24, 2020Manufacturing and Production Cancer, Roche, acute myeloid leukamia
Roche has announced that its clinical trials for Venclexta/Venclyzto combination with azacitidine have met its primary endpoints of overall survival …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
